L
Luciana Muñoz
Researcher at Mayo Clinic
Publications - 9
Citations - 112
Luciana Muñoz is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Chemistry & Clinical endpoint. The author has an hindex of 3, co-authored 8 publications receiving 55 citations.
Papers
More filters
Journal Article
Development of a hyperimmune equine serum therapy for COVID-19 in Argentina
Vanesa Zylberman,Santiago Sanguineti,Andrea Pontoriero,Sandra V Higa,Maria Laura Cerutti,Maria Laura Cerutti,Susana M Morrone Seijo,Romina Paola Pardo,Luciana Muñoz,María E Acuña Intrieri,María E Acuña Intrieri,Vanina Alzogaray,Martín Avaro,Estefanía Benedetti,Paula Mercedes Berguer,Laura Bocanera,Lucas Bukata,Marina S Bustelo,Ana M. Campos,Mariana Colonna,Elisa Correa,Lucía Cragnaz,María Elena Dattero,María Dellafiore,Sabrina Foscaldi,Joaquín V González,Luciano L Guerra,Sebastián Klinke,María S. Labanda,Constanza Lauché,Juan Carlos Lozano López,Anabela M Martínez,Lisandro H. Otero,Elías H Peyric,Pablo F Ponziani,Romina Ramondino,Jimena Rinaldi,Santiago Rodríguez,Javier E Russo,Mara Russo,Soledad L Saavedra,Mauricio Seigelchifer,Santiago Sosa,Claudio Vilariño,Patricia López Biscayart,Esteban Corley,Linus Spatz,Elsa Baumeister,Fernando A. Goldbaum,Fernando A. Goldbaum +49 more
TL;DR: In this paper, a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein was presented, which showed around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma.
Journal ArticleDOI
RBD-specific polyclonal F(ab´) 2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.
Gustavo Lopardo,Waldo H. Belloso,Esteban Nannini,Mariana Colonna,Santiago Sanguineti,Vanesa Zylberman,Vanesa Zylberman,Luciana Muñoz,Martín Dobarro,Gabriel Lebersztein,Javier Farina,Gabriela Vidiella,Anselmo Bertetti,Favio Crudo,Maria Fernanda Alzogaray,Laura Barcelona,Ricardo Teijeiro,Sandra Lambert,Darío Scublinsky,Marisa Iacono,Vanina Stanek,Rubén Solari,Pablo Cruz,Marcelo Martín Casas,Lorena Abusamra,Héctor Lucas Luciardi,Alberto Cremona,Diego Caruso,Bernardo de Miguel,Santiago Perez Lloret,Santiago Perez Lloret,Santiago Perez Lloret,Susana Millán,Yael Kilstein,Ana Pereiro,Omar Sued,Pedro Cahn,Linus Spatz,Fernando Alberto Goldbaum +38 more
TL;DR: In this article, the authors conducted a double-blind, randomized, placebo-controlled trial to assess efficacy and safety of equine polyclonal antibodies (INM005) in hospitalized adult patients with moderate and severe COVID-19 pneumonia in 19 hospitals of Argentina.
Journal Article
Desarrollo de un suero equino hiperinmune para el tratamiento de COVID-19 en Argentina, Development of a hyperimmune equine serum therapy for COVID-19 in Argentina
Vanesa Zylberman,Santiago Sanguineti,Andrea Pontoriero,S. V. Higa,Maria Laura Cerutti,S. M. Morrone Seijo,Romina Paola Pardo,Luciana Muñoz,M. E. Acuna Intrieri,Vanina Alzogaray,Martín Avaro,Estefanía Benedetti,Paula Mercedes Berguer,L. Bocanera,Lucas Bukata,M. S. Bustelo,Ana M. Campos,Mariana Colonna,E. Correa,L. Cragnaz,María Elena Dattero,M. Dellafiore,Sabrina Foscaldi,J. V. Gonzalez,L. L. Guerra,Sebastián Klinke,María S. Labanda,Constanza Lauché,Juan Carlos Lozano López,A. M. Martinez,Lisandro H. Otero,E. H. Peyric,P. F. Ponziani,R. Ramondino,Jimena Rinaldi,Santiago Rodríguez,J. E. Russo,Mara Russo,S. L. Saavedra,Mauricio Seigelchifer,Santiago Sosa,C. Vilarino,P. Lopez Biscayart,Esteban Corley,Linus Spatz,Elsa Baumeister,Fernando A. Goldbaum +46 more
TL;DR: A new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein is presented, which shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma.
Journal Article
[Development of a product anti-Shiga toxin for prevention of the hemolytic uremic syndrome].
Yanina Hiriart,Romina Paola Pardo,Lucas Bukata,Constanza Lauché,Luciana Muñoz,Mariana Colonna,Fernando Alberto Goldbaum,Santiago Sanguineti,Vanesa Zylberman +8 more
TL;DR: A new treatment capable of neutralizing the toxic effect of Stx and its variants is described, consisting of F(ab')2 fragments from an equine antiserum whose efficacy and potency against Stx1 and Stx2 were proved in different preclinical models and were shown to be safe in animals.
Journal ArticleDOI
Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.
Facundo José Salinas,Belkis Ester Marelli,Santiago Sanguineti,Fernando Alberto Goldbaum,Luciana Muñoz,Lucas Etchevers,Paula Silvestrini,Ulises Sebastián Notaro,Natalia Raquel Salvetti,Vanesa Zylberman,Hugo Hector Ortega +10 more
TL;DR: In this paper, in vivo and ex vivo NIR images were taken at 1, 12, 24, 36, 48, 49, 60, 72, 84, 96, 108, 120, 132 and 144h after the first intravenous injection.